BioSyent Future Growth
Future criteria checks 1/6
BioSyent is forecast to grow revenue at 12.9% per annum. EPS is expected to grow by 18.8% per annum.
Key information
n/a
Earnings growth rate
18.8%
EPS growth rate
| Pharmaceuticals earnings growth | 56.3% |
| Revenue growth rate | 12.9% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 21 Nov 2024 |
Recent future growth updates
Recent updates
BioSyent's (CVE:RX) Shareholders Will Receive A Bigger Dividend Than Last Year
Feb 04
BioSyent (CVE:RX) Is Paying Out A Dividend Of CA$0.045
Nov 23BioSyent's (CVE:RX) Dividend Will Be CA$0.045
Aug 30BioSyent's (CVE:RX) Profits May Not Reveal Underlying Issues
Mar 22BioSyent (CVE:RX) Will Pay A Larger Dividend Than Last Year At CA$0.045
Feb 09BioSyent Inc.'s (CVE:RX) Intrinsic Value Is Potentially 38% Above Its Share Price
Apr 14BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 19Declining Stock and Solid Fundamentals: Is The Market Wrong About BioSyent Inc. (CVE:RX)?
Mar 17BioSyent (CVE:RX) Shareholders Booked A 33% Gain In The Last Year
Feb 18
Here's Why BioSyent's (CVE:RX) Statutory Earnings Are Arguably Too Conservative
Jan 28BioSyent Inc. (CVE:RX) Shares Could Be 30% Below Their Intrinsic Value Estimate
Jan 07BioSyent Inc.'s (CVE:RX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Dec 17Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?
Dec 02Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 46 | N/A | N/A | N/A | 1 |
| 12/31/2025 | 42 | N/A | N/A | N/A | 1 |
| 12/31/2024 | 35 | N/A | N/A | N/A | 1 |
| 9/30/2024 | 35 | 7 | 2 | 7 | N/A |
| 6/30/2024 | 34 | 7 | 2 | 3 | N/A |
| 3/31/2024 | 33 | 7 | 7 | 7 | N/A |
| 12/31/2023 | 32 | 6 | 5 | 5 | N/A |
| 9/30/2023 | 31 | 6 | 6 | 7 | N/A |
| 6/30/2023 | 29 | 5 | 5 | 5 | N/A |
| 3/31/2023 | 27 | 5 | 3 | 4 | N/A |
| 12/31/2022 | 28 | 5 | 4 | 5 | N/A |
| 9/30/2022 | 28 | 6 | 4 | 5 | N/A |
| 6/30/2022 | 28 | 6 | 6 | 6 | N/A |
| 3/31/2022 | 28 | 6 | 5 | 5 | N/A |
| 12/31/2021 | 29 | 6 | 5 | 5 | N/A |
| 9/30/2021 | 27 | 5 | 5 | 5 | N/A |
| 6/30/2021 | 26 | 4 | 4 | 4 | N/A |
| 3/31/2021 | 24 | 4 | 5 | 6 | N/A |
| 12/31/2020 | 22 | 4 | 7 | 7 | N/A |
| 9/30/2020 | 22 | 4 | 10 | 8 | N/A |
| 6/30/2020 | 23 | 5 | 6 | 7 | N/A |
| 3/31/2020 | 23 | 5 | 4 | 5 | N/A |
| 12/31/2019 | 21 | 4 | 4 | 4 | N/A |
| 9/30/2019 | 22 | 5 | 1 | 4 | N/A |
| 6/30/2019 | 21 | 5 | 4 | 5 | N/A |
| 3/31/2019 | 22 | 6 | 5 | 6 | N/A |
| 12/31/2018 | 22 | 6 | 6 | 6 | N/A |
| 9/30/2018 | 22 | 5 | 6 | 7 | N/A |
| 6/30/2018 | 22 | 6 | N/A | 7 | N/A |
| 3/31/2018 | 21 | 5 | N/A | 7 | N/A |
| 12/31/2017 | 21 | 5 | N/A | 7 | N/A |
| 9/30/2017 | 20 | 5 | N/A | 6 | N/A |
| 6/30/2017 | 19 | 5 | N/A | 5 | N/A |
| 3/31/2017 | 18 | 4 | N/A | 5 | N/A |
| 12/31/2016 | 18 | 4 | N/A | 4 | N/A |
| 9/30/2016 | 17 | 4 | N/A | 3 | N/A |
| 6/30/2016 | 17 | 4 | N/A | 4 | N/A |
| 3/31/2016 | 16 | 4 | N/A | 4 | N/A |
| 12/31/2015 | 15 | 4 | N/A | 3 | N/A |
| 9/30/2015 | 15 | 4 | N/A | 3 | N/A |
| 6/30/2015 | 14 | 4 | N/A | 3 | N/A |
| 3/31/2015 | 13 | 4 | N/A | 3 | N/A |
| 12/31/2014 | 12 | 3 | N/A | 4 | N/A |
| 9/30/2014 | 11 | 3 | N/A | 3 | N/A |
| 6/30/2014 | 10 | 3 | N/A | 2 | N/A |
| 3/31/2014 | 9 | 2 | N/A | 2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if RX's forecast earnings growth is above the savings rate (2.4%).
Earnings vs Market: Insufficient data to determine if RX's earnings are forecast to grow faster than the Canadian market
High Growth Earnings: Insufficient data to determine if RX's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: RX's revenue (12.9% per year) is forecast to grow faster than the Canadian market (5.3% per year).
High Growth Revenue: RX's revenue (12.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 16:09 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioSyent Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Martin | Bloom Burton & Co. |
| Scott Curtis | Cantor Fitzgerald Canada Corporation |
| Tania Armstrong-Whitworth | Cormark Securities Inc. |